Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMEZ0H5)

Drug Name
LY2963016 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-1/2 diabetes 5A10-5A11 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMEZ0H5

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin (INS) TTZOPHG INS_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Insulin (INS) DTT INS 0.848 2.138 0.379 0.926
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type-1/2 diabetes
ICD Disease Classification 5A10-5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin (INS) DTT INS 6.70E-01 -0.12 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02302716) A Study of LY2963016 Compared to LANTUS in Adult Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2 Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.